Known as our Extreme Diversity platform, our proprietary macrocyclic peptide chemistry technology allows us to produce synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

DARA Biosciences, Inc. (NasdaqCM: DARA ) is a Raleigh, North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA. The Company has a pipeline of diverse drug candidates at various stages of development, with 82 granted patents and 56 pending applications (U.S. and foreign). The first drug candidate KRN5500 has successfully completed a Phase 2 clinical trial treating cancer patients for neuropathic pain. KRN5500 met its primary endpoint and was statistically significantly (p=0.03) better than placebo. A second Phase 2 clinical trial is planned to start during the second half of 2010. The second drug candidate DB959 is a highly selective, non-thiazolidinedione (TZD), first-in-class dual PPAR (peroxisome proliferator activated receptor) delta/gamma agonist in development for type 2 diabetes. A Phase 1 clinical study for DB959 is underway and the Company plans to announce results in the second half of 2010. In addition, DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities. PPAR receptors are found throughout the human body and recent publications report that PPAR agonists may be useful in the treatment of Alzheimer’s disease, cystic fibrosis, liver disease, and a variety of autoimmune diseases. Because its diverse PPAR library has the potential to address the unmet medical needs of these diseases, the Company plans to explore several of these indications.

We depend heavily on our executive officers, directors, and principal consultants and the loss of their services would materially harm our business.

Schnaper, H. W. et al. TGF-beta signal transduction in chronic kidney disease. Frontiers in bioscience. 14, 2448–2465 (2009).

Thanks for chiming in with that article. As usual we fail to measure the important things like insulin, IGF, and ferritin

GeneThera Inc. (OTCPK: GTHR ) GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne’s disease.

I found a stable supplier of Sulforaphane their product is called prostaphane and is made by a french company.

Rats’ carotid aortas were isolated, fixed in formalin (10%), processed for paraffin sectioning (3 mm thick) and stained with hematoxylin-eosin (H&E). The lumen of blood vessels, vascular walls and vascular endothelial cells of the carotid aortas were observed with microscope.

Treatment of CHO-K1 cells expressing human HCN1 channels by MβCD resulted in reduced current density compared to untreated control cells (Fig. 1A,B). To verify that this effect was specific to the effects of membrane cholesterol, and not due to unspecific effects of MβCD, we also examined the effect of 30 μM mevastatin, which blocks cholesterol synthesis. Similar to the effect of MβCD, current densities were also reduced in cells treated with mevastatin. While there was a trend towards an increase in the current density with the enrichment of cellular cholesterol by MβCD/cholesterol (P = 0.12), statistical significance could not be resolved. Both depletion and enrichment had no effect on the steady-state activation properties of HCN1 channels (Fig. 1C; Table 1). HCN1 activation currents can be described by a dual-exponential function, whose fast time component (τfast) was unchanged by modulation of membrane cholesterol (Fig. 1D), however, cholesterol depletion reduced the slow component of activation (τslow) by 2-fold (Fig. 1E). No observable effect on HCN1 deactivation kinetics could be discerned.

ENDOSTOCK/STOCK.ADOBE.COMIt is not unusual to hear of cGMP and quality failings in API and finished drug manufacturing, especially as more functions are outsourced. Between October 2016 and September 2017, out of 3343 citations for quality systems failures, roughly 11% were likely due to problems with supplier quality management, according to Phil Johnson, senior principal for quality and compliance services at IQVIA (1).

Hi Mark You seem like a ZenMaster. I’ve always wanted to go to Bhutan, the Buddhist kingdom, maybe next year.

No person may be appointed as an external director if such person is a relative of a controlling shareholder or if such person, a relative, partner or employer of such person, or anyone to whom such person is directly or indirectly subordinate, or any entity under such person’s control, has or had, on or within the two years preceding the date of such person’s appointment to serve as an external director, any affiliation with the company to whose board of directors the external director is proposed to be appointed, with any controlling shareholder of the company, with a relative of such controlling shareholder, or with any entity controlled, on the date of such appointment or within the preceding two years, by the company or by a controlling shareholder of the company. If the company has no controlling shareholder or a shareholder holding 25% or more of the company’s voting rights, a person may not serve as an external director if the person has any affiliation, at the time of the appointment, to the chairman of the board of directors, the chief executive officer or the most senior financial officer of the company, or to a shareholder holding 5% or more of the outstanding shares or voting rights of the company.